Physician profile
Mark A Jara
NPI 1942646062
$12,271.80
in general payments reported to CMS, 2019-2025
11 companies · $11K in 2025
The $11K reported for 2025 was more than what 90% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $376 · 2023: $415 · 2024: $151 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $5,676 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,500 · Food and Beverage: $1,139 · Travel and Lodging: $559 · Education: $22.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $5,676.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,500.00 |
| Food and Beverage | $1,138.50 |
| Travel and Lodging | $559.33 |
| Education | $22.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $6,259.93 | 2025 | Mycapssa |
| Abbott Laboratories | $4,500.00 | 2025 | Freestyle Libre |
| Amgen INC. | $373.96 | 2025 | Tepezza |
| Lilly USA, LLC | $301.49 | 2022-2024 | Retevmo, Jardiance, Zepbound |
| Janssen Scientific Affairs, LLC | $293.18 | 2022-2025 | Xarelto, Imbruvica, Carvykti |
| Amryt Pharma Holdings LTD | $219.30 | 2022-2023 | Mycapssa |
| Neurocrine Biosciences, INC. | $136.51 | 2025 | |
| Exelixis INC. | $132.43 | 2024 | Cabometyx |
| Acella Pharmaceuticals, LLC | $22.00 | 2023 | NP Thyroid 60 |
| Corcept Therapeutics | $17.09 | 2025 | Korlym |
| Novo Nordisk INC | $15.91 | 2023 | Rybelsus, Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Jara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.